Product image of Letrozole Bristol Laboratories (Letrozole) supplied by GNH India

Letrozole Bristol Laboratories

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Bristol Laboratories (Letrozole)

Letrozole, the active ingredient in Letrozole Bristol Laboratories, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat postmenopausal estrogen receptor‑positive breast cancer, both in the adjuvant and metastatic settings.

GNH India supplies Letrozole Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to EU GMP standards and provides regulatory‑approved batches to hospitals, pharmacies and procurement teams.

Manufacturer / TM Owner

Bristol Laboratories Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Letrozole is an aromatase inhibitor used in hormone‑responsive breast cancer management.
  • Postmenopausal estrogen receptor‑positive breast cancer: reduces recurrence risk and disease progression.
  • Adjuvant treatment of hormone‑responsive breast cancer: improves disease‑free survival after surgery.
  • Metastatic breast cancer: provides disease control when other endocrine therapies are unsuitable.

How It Works

  • Letrozole selectively and non‑steroidally inhibits the aromatase enzyme, which converts androstenedione and testosterone to estrone and estradiol. By blocking this conversion, systemic estrogen levels fall, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing or halting tumor progression.

Side Effects

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Arthralgia: joint pain or stiffness.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.
  • Headache: intermittent pain.
  • Increased sweating.

Serious or Rare Side Effects

  • Severe liver injury: elevated transaminases or hepatitis.
  • Bone fracture: decreased bone mineral density leading to fractures.
  • Deep vein thrombosis or pulmonary embolism.
  • QT interval prolongation on ECG.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

  • When prescribing Letrozole, clinicians should consider several safety precautions.
  • Pregnancy: contraindicated; teratogenic risk (Category X).
  • Bone health: monitor bone mineral density; consider calcium/vitamin D supplementation.
  • Liver function: assess hepatic enzymes before initiation and periodically.
  • Cardiovascular risk: evaluate history of thromboembolic events.
  • Drug interactions: review concomitant medications for CYP3A4 inducers or inhibitors.
  • Store below 25°C: keep in original packaging, protect from moisture.

Avoid Interactions

Letrozole may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Estrogen replacement therapy: antagonizes Letrozole’s aromatase inhibition.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations.
  • Tamoxifen: opposing mechanisms may diminish therapeutic benefit.
  • Warfarin: increased anticoagulant effect, requiring INR monitoring.
  • Anticonvulsants that induce hepatic enzymes.

Moderate Interactions (Monitor Closely)

  • CYP2C19 inhibitors (e.g., fluconazole): may raise Letrozole levels.
  • Selective serotonin reuptake inhibitors: potential additive hot‑flash effect.
  • Statins metabolised by CYP3A4: monitor for altered lipid‑lowering response.

Frequently Asked Questions

Letrozole Bristol Laboratories is an oral aromatase inhibitor indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer, including adjuvant therapy after surgery and control of metastatic disease in patients whose tumors depend on estrogen for growth.

Letrozole blocks the aromatase enzyme, which converts adrenal and ovarian androgens into estrogens. By inhibiting this conversion, circulating estrogen levels fall, depriving hormone‑sensitive breast cancer cells of the estrogenic stimulus required for proliferation.

The specific dose of Letrozole is determined by the prescribing clinician based on the patient’s clinical condition, renal and hepatic function, and treatment goals. Dosage regimens are individualized and should follow the prescriber’s instructions.

Letrozole is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy due to known teratogenic risk. It is also not recommended for breastfeeding mothers because it may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole is a third‑generation, non‑steroidal aromatase inhibitor with high potency and a long half‑life, offering once‑daily dosing. Compared with earlier agents such as anastrozole, Letrozole often provides greater estrogen suppression, though individual response and tolerability may vary.

Letrozole tablets should be stored at or below 25 °C, in the original container, protected from moisture and direct light. Do not store in a bathroom or other humid environment, and keep out of reach of children.

Letrozole is taken orally, usually as a whole tablet with water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing and any required fasting.

Serious risks include severe liver injury, significant bone loss leading to fractures, and rare thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should report unexplained jaundice, persistent bone pain, or sudden swelling in the legs immediately to their healthcare provider.

Letrozole is contraindicated in pregnant women, nursing mothers, and premenopausal women unless ovarian suppression is in place. It should also be avoided in patients with known hypersensitivity to letrozole or any of its excipients, and in those with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT